Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients with Acute Heart Failure

Circulation Journal

Volumn 79, Issue 6, 2015, Pages 1237-1247

  Sato, Naoki ^a   Takahashi, Wataru ^b   Hirayama, Atsushi ^c   Ajioka, Masayoshi ^d   Takahashi, Naoto ^a   Okishige, Kaoru ^e   Wang, Xingli ^f   Maki, Akio ^h   Maruyama, Hideki ^h   Ebinger, Ursula ^f   Yamaguchi, Masayuki ^h   Pang, Yinuo ^g   Matsumoto, Hiroki ^h   Kawana, Masatoshi ⁱ  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^b Shinshu Ueda Medical Center   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOSEI GENERAL HOSPITAL   (Japan)

^e YOKOHAMA CITY MINATO RED CROSS HOSPITAL   (Japan)

^f Novartis Pharmaceuticals Corporation   (Japan)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^h NOVARTIS PHARMA K K   (Japan)

ⁱ TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Efficacy; Pharmacokinetics; Safety; Serelaxin; Tolerability

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CYSTATIN C; DOBUTAMINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; SERELAXIN; TROPONIN T; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

ACUTE HEART FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; CLINICAL ARTICLE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DEHYDRATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ESOPHAGUS CARCINOMA; EXERCISE; FEMALE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; HYPOTENSION; IMMUNOGENICITY; INTESTINE ISCHEMIA; JAPANESE (PEOPLE); LIKERT SCALE; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PERITONEUM METASTASIS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE; ACUTE DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; METABOLIC CLEARANCE RATE; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; COMORBIDITY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSPNEA; FEMALE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RELAXIN; TREATMENT OUTCOME;

EID: 84930067739     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0227     Document Type: Article

References (27)

1. Kajimoto K, Sato N, Takano T; investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Relation of left ventricular ejection fraction and clinical features or co-morbidities to outcomes among patients hospitalized for acute heart failure syndromes. Am J Cardiol 2015; 115: 334 – 340.
2. Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: Future projection of heart failure in Japan to the year 2055. Circ J 2008; 72: 489 – 491.
3. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J 2013; 77: 2209 – 2217.
4. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 557 – 573.
5. Fang J, Mensah GA, Croft JBKeenan NL., Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008; 52: 428 – 434.
6. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123 – 1133.
7. Metra M, Felker GM, Zacà V, Bugatti S, Lombardi C, Bettari L, et al. Acute heart failure: Multiple clinical profiles and mechanisms require tailored therapy. Int J Cardiol 2010; 144: 175 – 179.
8. Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev 2007; 12: 91 – 95.
9. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005; 96: 11G – 17G.
10. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787 – 1847.
11. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147 – e239, doi:10.1016/j.jacc.2013.05.019.
12. JCS Joint Working Group. Guidelines for treatment of acute heart failure (JCS 2011): Digest version. Circ J 2013; 77: 2157 – 2201.
13. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: Lessons learned and directions forward. Circ Heart Fail 2010; 3: 314 – 325.
14. Greene SJ, Shah AN, Butler J, Ambrosy AP, Anker SD, Chioncel O, et al. Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. Am Heart J 2014; 168: 142 – 149.
15. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: Review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010; 7: 75 – 82.
16. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: From basic science to clinical therapy. Nat Rev Cardiol 2010; 7: 48 – 58.
17. Conrad KP, Shroff SG. Effects of relaxin on arterial dilation, remodeling, and mechanical properties. Curr Hypertens Rep 2011; 13: 409 – 420.
18. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): A multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429 – 1439.
19. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet 2013; 381: 29 – 39.
20. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAXAHF) development program: Correlation with outcomes. J Am Coll Cardiol 2013; 61: 196 – 206.
21. Dahlke M, Ng D, Yamaguchi M, Machineni S, Berger S, Canadi J, et al. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations. J Clin Pharmacol 2015; 55: 415 – 422.
22. Kobalava Z, Halabi A, Zähringer A, Pang Y, Dahlke M. No effect of hepatic impairment on the pharmacokinetics of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure. Circulation 2013; 128: A12961.
23. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomised controlled trial. JAMA 2002; 287: 1541 – 1547.
24. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JGF, Jondeau G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: The VERITAS randomised controlled trials. JAMA 2007; 298: 2009 – 2019, doi: 10.1001/jama.298.17.2009.
25. Torre-Amione G, Milo-Cotter O, Kaluski E, Perchenet L, Kobrin I, Frey A, et al. Early worsening heart failure in patients admitted for acute heart failure: Time course, hemodynamic predictors, and outcome. J Card Fail 2009; 15: 639 – 644.
26. Cotter G, Metra M, Weatherley BD, Dittrich HC, Massie BM, Ponikowski P, et al. Physician-determined worsening heart failure: A novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes. Cardiology 2010; 115: 29 – 36.
27. Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: The need for a uniform approach. Eur Heart J 2008; 29: 816 – 824.